Floatz logo

Ndi-219216

Advanced Solid Tumors Cancer

Nimbus Wadjet, Inc.Phase 1/2Active
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
89/ 100

Competitive context

14 Active assets in the Advanced Solid Tumors Cancer cohort.

Asset / SponsorPhaseRating
Budigalimab
AbbVie
Phase 1CCC
MAB HUMANIZED (IGG1) ANTI P43489 (TNR4_HUMAN) (ABBV368)
AbbVie
Phase 1CCC
gfh375
Genfleet Therapeutics (Shanghai) Inc.
Phase 1/2CC
IMMUNOGLOBULIN G1-KAPPA, ANTI-(HOMO SAPIENS EGFR (EPIDERMAL GROWTH FACTOR RECEPTOR, RECEPTOR TYROSINE-PROTEIN KINASE ERBB-1, ERBB1, HER1, HER-1, ERBB)), MONOCLONAL ANTIBODY CONJUGATED TO THE PYRROLOBENZODIAZEPINE (PDB) DIMER SGD-1882GAMMA1 HEAVY CHAIN (1-446) (VH (HOMO SAPIENS IGHV4-30-4*01 (81.4%)-(IGHD)-IGHJ4*01 (92.9%)) (9.7.9) (1-116)-HOMO SAPIENS IGHG1*03V, G1M3>G1M17, NG1M1 (CH1 R120>K (213) (117-214), HINGE (215-229), CH2 S3>C (238) (230-339), CH3 E12 (355), M 14 (357) (340-444), CHS (445-446)) (117-446)), (219-214')-DISULFIDE WITH KAPPA LIGHT CHAIN (1'-214') (V-KAPPA (MUS MUSCULUS IGKV14-100*01 (86.3%)-IGKJ1*01 (100%)/HOMO SAPIENS IGKV1-12*01 (74.7%)-IGKJ4*01 (90.9%)) (6.3.9) (1'-107')-HOMO SAPIENS IGKC*01 (100%), KM3 A45.1 (153), V101 (191) (108'-214'))DIMER (225-225'':228-228'')-BISDISULFIDECONJUGATED, ON TWO SITE-SPECIFIC DRUG ATTACHMENT ENGINEERED CYSTEINES (C238, C238''), TO PYRROLOBENZODIAZEPINE (PDB) DIMERS SGD-1882, VIA A CATHEPSIN-CLEAVABLE MALEIMIDOCAPROYLVALINE-ALANINE (MC-VAL-ALA) TYPE LINKER
AbbVie
Phase 1CC
ABT-700-VCMMAE
AbbVie
Phase 1CC

View all 20 →

Same molecule, other indications

Ndi-219216 is also rated in:

MSI-H CancerDormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →